药厂巨型Beeringer Ingelheim在瑞士开通了27.54M的癌症研究设施。 Pharma giant Boehringer Ingelheim opens a $27.54M cancer research facility in Switzerland.

Boehringer Ingelheim在瑞士巴塞尔开设了一个新的2 754万美元的研究设施,为其子公司NBE治疗学开发用于高级癌症治疗的抗体药物共产体(ADCs)。 Boehringer Ingelheim has opened a new $27.54 million research facility in Basel, Switzerland, for its subsidiary NBE Therapeutics to develop antibody-drug conjugates (ADCs) for advanced cancer treatments. 该设施将容纳约50名科学家,并旨在达到瑞士的可持续性标准。 The facility will house around 50 scientists and is designed to meet Swiss sustainability standards. 这项投资支持Boehringer Ingelheim扩大肿瘤研究和开发创新性癌症疗法的目标。 This investment supports Boehringer Ingelheim's goal of expanding its oncology research and developing innovative cancer therapies.